Knoxville, Tenn. – (August 31, 2015) – EDP Biotech Corporation, (EDP), a global in vitro diagnostic innovator of simple, blood-based cancer diagnostic tests, announces the publication of key study data for its ColoMarkerÒ ELISA kit. In this clinical research study, ColoMarker demonstrated an overall sensitivity of 97.7% with specificity of 84.4% for all colorectal cancer detection and a nearly 100% sensitivity for early stage (I, II and III) colorectal cancer. Additionally, ColoMarker demonstrated 40% sensitivity to adenomatous polyps. ColoMarker received CE Mark approval as an aid in the detection of early stage colorectal cancer in late 2014.
Topics
Recent Posts
- Existing FDA-approved blood test for colorectal cancer screening, ColoHealth™, formerly known as Epi proColon.
- Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening
- OPEN OPPORTUNITIES
- Colorectal Cancer Awareness Month: New test for prevention and early detection
- Living East TN-New Day Diagnostics with New Screening Tool for National Colorectal Cancer Awareness Month